

Protective effect of *Lactobacillus rhamnosus* 231 against N-Methyl-N'-nitro-N-nitrosoguanidine in animal model

Viral Gosai,¹ Padma Ambalam,^{2,†,*} Maya Raman,³ C.R. Kothari,² R.K. Kothari,⁴ B.R.M. Vyas⁵ and Navin R. Sheth¹

¹Department of Pharmacy; Saurashtra University; Rajkot, India; ²Department of Biotechnology; Christ College; Rajkot, India; ³School of Industrial Fisheries; Cochin University of Science and Technology; Kerala, India; ⁴Department of Microbiology; Christ College; Rajkot, India; ⁵Department of Biosciences; Saurashtra University; Rajkot, India

[†]Current Address: Labmedicin, Klinisk Mikrobiologi; Lund, Sweden

Keywords: *Lactobacillus rhamnosus* (Lr 231), colorectal cancer, histopathological, azoreductase, nitroreductase, MNNG

The protective effect of *Lactobacillus rhamnosus* 231 (Lr 231) against potent carcinogen N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG) in the rat model is studied. Daily feeding with Lr 231 improved the body weight of male Wistar rats compared with control groups. Fecal azoreductase ($p < 0.001$) and nitroreductase ($p < 0.01$) enzyme activity decreased significantly in Lr 231 group in comparison with control groups that received only phosphate buffer or MNNG. Oral administration of MNNG led to a significant increase in Glutathione transferase (GST) while Glutathione reductase (GSH) showed decreased activity. Conversely, feeding Lr 231 showed significantly increased GSH and decreased GST activity in comparison to the MNNG group, emphasizing the protection provided by Lr 231 against MNNG. Histopathological analysis of liver, spleen and colon showed decreased signs of inflammation in the Lr 231 group. The present study highlights that inclusion of active Lr 231 in regular diets could be used to prevent MNNG induced colon carcinoma.

Introduction

Colorectal cancer is multifactorial; and epidemiological, etiological and experimental studies indicate that this disease is associated with the accumulation of relevant genetic changes and DNA damage in the target tissue.¹ Colon cancer is the second to third most frequent type of cancer in Western countries. Exposure of genotoxic compounds or carcinogens to the colon and rectum are the primary cause for DNA damage in these tissues that lead to cancer. These carcinogens are of exogenous origin or endogenous origin. Heterocyclic amines or polycyclic aromatic hydrocarbons are exogenous, which are formed due to improper handling of food. The N-nitroso-compounds, fecapentaenes and bile acids are known to form endogenously.² The awareness of this disease has augmented the increased consumption of fruits, vegetables and food rich in total dietary fiber that tend to reduce the risk of development of colon cancer.^{3,4} Prebiotics, probiotics, synbiotics might be a feasible chemo-preventive measure against colon cancer in humans, and may present a novel therapeutic or preventive option.^{5,6} A number of studies have recently emphasized the beneficial therapeutic effects of Lactic acid bacteria (LAB) as a probiotic.^{7,8} LAB and its metabolites exhibit antimutagenic and anticarcinogenic properties in vitro and in vivo.^{9–11} Oral supplementation of *L. acidophilus* in humans reduces activity of fecal bacterial enzymes such as β -glucuronidase, nitroreductase

and azoreductase that activate pro-carcinogens into carcinogen; and facilitate in their excretion through feces and urine.¹²

MNNG (N-Methyl-N'-nitro-N-nitrosoguanidine), a direct-acting potent carcinogen, causes cancer in all laboratory-tested species such as mouse, rat, hamster, rabbit and dog and is preferred as a representative compound for endogenously formed N-nitroso compounds.¹³ Diet high in meat could induce a 3-fold increase of endogenous N-nitroso compound production in human gut system.¹⁴

L. rhamnosus 231 (Lr 231) exhibits in vitro binding of MNNG resulting in biotransformation and detoxification.¹⁵ The present study determines the protective effect of Lr 231 against MNNG in rat model.

Results

Feed intake (FI) and body weight (BW) variations with Lr 231 intake. FI and BW were increased in Lr 231 group compared with MNNG-fed and control group (Table 1). The MNNG-fed group showed decreased FI and reduced BW, however, it was statistically insignificant.

Fecal azoreductase and fecal nitroreductase assay show variation in the Lr 231 group in comparison to the MNNG-fed group and control groups. Fecal azoreductase and nitroreductase activities are shown in Figure 1A and B, respectively. Lr 231

*Correspondence to: Padma Ambalam; Email: padma_ambalam@yahoo.com
Submitted: 09/02/11; Revised: 11/10/11; Accepted: 11/13/11
<http://dx.doi.org/10.4161/gmic.2.6.18755>

Table 1. Variation in food intake (FI) and body weight (BW) in rat models when treated with only MNNG and Lr 231 group

Parameter	Control (g)	Only MNNG (g)	Lr 231 group (g)
FI- week 1	85.4	89.3	107.9
FI- week 2	108.6	97.6	113.0
FI- week 3	118.6	105.3	128.6
FI- week 4	121.7	110.5	129.8
FI- week 5	128.1	119.6	131.7
BW- week 1	196.1	162.2	228.0
BW- week 2	209.5	214.0	231.1
BW- week 3	231.7	234.9	256.3
BW- week 4	249.7	247.6	273.1
BW- week 5	251.3	251.0	295.1

Control group was fed with phosphate buffer; Values are mean \pm SD of different n = 6.

group showed significantly reduced azoreductase ($p < 0.001$) and nitroreductase activity ($p < 0.01$) compared with the control groups. The MNNG-fed group showed a marked increase in azoreductase ($0.899 \mu\text{moles}/\text{min}/\text{mg}$) and nitroreductase ($0.937 \mu\text{moles}/\text{min}/\text{mg}$) activities on week five in comparison with azoreductase ($0.687 \mu\text{moles}/\text{min}/\text{mg}$) and nitroreductase ($1.057 \mu\text{moles}/\text{min}/\text{mg}$) of control group.

Antioxidative enzymes assay. Liver, spleen and colon in the MNNG-fed group showed GST activity of 0.14, 0.04 and $0.11 \mu\text{mole}/\text{min}/\text{mg}$, respectively, which was significantly higher than the control group. Feeding Lr 231 decreased GST activity in liver ($0.08 \mu\text{mole}/\text{min}/\text{mg}$), spleen ($0.01 \mu\text{mole}/\text{min}/\text{mg}$) and colon ($0.028 \mu\text{mole}/\text{min}/\text{mg}$). Liver, spleen and colon in the MNNG-fed group showed GSH activity of 6.1, 6.8 and $1.8 \mu\text{mol}/\text{mg}$, respectively and was significantly lower than the control group having GSH activity as 16.1, 24.6 and $5.1 \mu\text{mole}/\text{min}/\text{mg}$, respectively. Feeding Lr 231 increased GSH activity in liver ($11.6 \mu\text{mole}/\text{min}/\text{mg}$), spleen ($18.5 \mu\text{mole}/\text{min}/\text{mg}$) and colon ($3.3 \mu\text{mole}/\text{min}/\text{mg}$) compared with MNNG group nevertheless it was lesser than control group (Table 2).

Histopathological assay. Histopathology of liver, spleen and colon tissue was performed and severity of the inflammation and change in the shape of cells were evaluated (Fig. 2). Liver and colon sections of the MNNG group showed mild necrosis and inflammation. The Lr 231 group showed reduced inflammation in colon and cells appeared to be normal in liver. Histopathological scoring showed that inflammation in the tissue sections were either reduced or not visible in the Lr 231 group (Table 3).

Discussion

Colon cancer and other forms of cancer are diet-dependent and dose-dependent.^{3,16} Meat and dietary fat act as the primary risk factors. Cancer induction is a complex multi-step process caused by the accumulation of mutagens and induction of the mutation of tumor suppressor genes.³ Lactobacilli can influence several mechanisms possibly linked to carcinogenesis such as preventing mutations, binding mutagens, inhibiting bacterial enzymes that

converts procarcinogens to carcinogens in the colon, decreasing pH in the colon lumen or activating the immune system.⁹

In this study we report the protective role of Lr 231 against potent mutagen MNNG in the male Wister rat model. Potential probiotic human strain Lr 231 was isolated from healthy human feces. It possesses antimicrobial activity against several human pathogens and food spoilage organisms and it is partially attributed to low molecular weight glycopeptide.¹⁷ Lr 231 exhibits in vitro binding and antimutagenic activity against potent mutagens AO, MNNG and MeIQx.¹⁷

Lr 231 had positive influence on the rats' appetite, even though they were fed with MNNG on day 22 and 28. In control and Lr 231 group, increase in body weight and feed intake showed a similar fashion. In MNNG-fed group body weight increased and feed intake was comparatively lesser than other groups. Even though, the feed intake rate was lesser in Lr 231 group after third week, the body weight did not change indicating no significant adverse effects of Lr 231 on feed intake and body weight.

Azoreductase and nitroreductase are potential mediators of colon carcinogenesis. These enzymes are involved in the conversion of pro-carcinogens to carcinogens that increases risk of colon cancer.^{18,19} Gut microflora consisting of both harmful and beneficial bacteria differ in their enzyme activity. Reduction in fecal azoreductase and nitroreductase activity in Lr 231 group in comparison to control and MNNG group indicates that continuous feeding of Lr 231 for four weeks protected rats against MNNG (Fig. 1). This could be due to the low fecal enzyme activity of lactobacilli involved in the conversion of promutagens to mutagens and carcinogens.²⁰ Nitroreductase activity remained similar in the MNNG group and control group while in Lr 231 group, it reduced significantly at the end of the experiment (Fig. 1). Lr 231 exhibit in vitro antibacterial activity against pathogenic bacteria.¹⁷ This property of Lr 231 might positively influence the gastrointestinal microflora, thereby, reducing their fecal enzymatic activity thereby protecting against MNNG. Rats fed with *L. acidophilus* showed reduced β -glucuronidase, nitroreductase and azoreductase activity.¹⁹ In another study, nitroreductase activity decreased by 30–40% in LAB treated groups in comparison with azoxy-methane alone in rat model.²¹

Antioxidant plays an important role in preventing the cells from oxidative damage. GSTs are important against oxidative stress and GSH are important cellular antioxidants. Lr 231 group showed a similar trend for GST and GSH activity, as that of control, whereas MNNG-fed groups had high GST and low GSH activity (Table 2). This improved GST and GSH activity in Lr 231 groups indicate the protective effect of Lr 231 against MNNG. Enzyme GST helps in sequestering carcinogens.²² They catalyze the conjugation of glutathione with mutagens containing electrophilic centers. It is important to deal with active electrophiles since they can react with macromolecules controlling cell growth such as DNA, RNA and proteins. Thus, GST plays an important role in detoxifying strong electrophiles having toxic, mutagenic and carcinogenic properties. Lr 231 group showed marked decrease in specific enzyme activity of GST compared with MNNG-fed group. GST activity was high in liver compared




Figure 1. Effect of Lr 231 on azoreductase and nitroreductase activity in the intestinal microflora of rat models, administered with MNNG on 22nd and 28th day. Azoreductase (A) and nitroreductase (B) activity decreased significantly ($p < 0.001$ and $p < 0.01$) in Lr 231 group in comparison to control group. Values are mean \pm SE of six different samples.

Table 2. Glutathione transferase and Glutathione reductase activity in rat liver, spleen and colon tissue homogenate at the end of the experiment

	GST ($\mu\text{moles/ min/ mg}$)			GSH ($\mu\text{moles /min/ mg}$)		
	Liver	Spleen	Colon	Liver	Spleen	Colon
Control	0.11 \pm 0.003	0.02 \pm 0.003	0.07 \pm 0.01	16.1 \pm 0.6	24.6 \pm 1.0	5.1 \pm 0.4
Only MNNG	0.14 \pm 0.004***	0.04 \pm 0.01*	0.11 \pm 0.011*	6.1 \pm 0.4***	6.8 \pm 0.6***	1.8 \pm 0.2***
Lr 231 group	0.08 \pm 0.004***	0.01 \pm 0.003*	0.028 \pm 0.008***	11.6 \pm 1.3**	18.5 \pm 1.2**	3.3 \pm 0.1***

Values are mean \pm SD, n = 6; Different superscripts indicates the significance level within the column *p < 0.05, **p < 0.01, ***p < 0.001.

with spleen and colon indicating elevated detoxification activity in this organs.²² The activity of GSH is used as indicator for oxidative stress and it is higher when ratio of GSSG to GSH is increased.²³ This ratio in Lr 231 group was lesser compared with the MNNG group showing lesser oxidative stress implying that feeding of Lr 231 have a protective effect against MNNG. GSH activity was higher in Lr 231 fed group compared with MNNG probably because Lr 231 bound to mutagen and made it less available. Lr 231 exhibits in vivo antioxidative activity and thereby preventing against oxidative epithelial damage caused by MNNG.

Histopathological sections of liver, spleen and colon show the severity of MNNG as a potent carcinogen. MNNG is the prime

cause of colon carcinoma in many animals including rats.¹³ It is evident in the current study that even at low doses, MNNG causes inflammation in the tissue sections. In MNNG group, no perivascular infiltration is observed indicating that necrosis and inflammation was solely induced by MNNG. In Lr 231 group this inflammation was reduced (Fig. 2).

The protective behavior of lactobacilli is dependent on its survival rate through the intestinal tract, multiplication and exerting probiotic effect in the colon. This confers the additional advantage of Lr 231 as probiotics or food adjuncts in preventing cancer. Previous studies reported that in vitro binding of MNNG of Lr 231 led to biotransformation and subsequent detoxification.¹⁵ Protection received by Lr 231 could be mainly due to




Figure 2. Histopathological sections showing necrosis and inflammation in (1) Liver (2) spleen and (3) colon cells with different groups (a) Control, (b) MNNG-fed and (c) Lr 231.

Table 3. Histopathological scoring and changes observed in the tissue sections of liver, spleen and colon

Group	Score	Changes observed
Colon		
Control 1	0	Normal intestinal mucosa
Only MNNG	2+	Congested blood vessels and inflammatory infiltration
Lr 231 group	+	Normal intestinal epithelium with minor inflammation
Liver		
Control 1	0	Hepatocytes with normal histology
Only MNNG	2+	Hepatic architectures, also focal area of necrosis is evident.
Lr 231 group	0	Normal size and appearance
Spleen		
Control 1	0	Normal spleen tissue with red and white areas
Only MNNG	0	Normal architecture with marked proliferation of the T lymphocytic cells
Lr 231 group	0	Normal arrangement of red and white areas with congestive splenic tissue

2+, Mild; +, Very mild; 0, No inflammation.

MNNG binding and detoxification, reduced fecal enzymes and antioxidative activity.

This work briefly describes the probiotic human strain Lr 231 possesses protective effect against potent colon carcinogen, MNNG. Feeding Lr 231 improved body weight in rats. Reduced fecal azoreductase and nitroreductase activity in Lr 231 group is an indirect evidence for the protective role of Lr 231 against MNNG. Histopathological study of liver, spleen and colon and reduced oxidative stress emphasize the protective effect of Lr 231. In vivo studies specify the significant role of Lr 231

against MNNG induced carcinoma; and suggests that addition of these in the diet will facilitate prevention against cancer. Additionally, determination of immunomodulatory properties of Lr 231 that help in preventing inflammatory lesion development by mutagen is required. Such studies will give us a better understanding and more in-depth knowledge concerning the total deactivating capacities of these important beneficial bacteria. Detail studies to determine mode of action of Lr 231 against MNNG is in progress.

Materials and Methods

Chemicals. MNNG, Sigma-Aldrich, St. Louis, Mo, USA was dissolved in di-methyl sulphoxide (DMSO). DMSO, 1-cholo-2, 4-dinitrobenzene (CDNB) and 5'-dithiobis-2-nitrobenzoic acid (DTNB) were purchased from SRL, India. Glutathione, MRS broth, M-nitro benzoic acid and EDTA were purchased from Himedia, India.

Bacterial strain. Potential probiotic human strain Lr 231 was isolated from feces of healthy human subjects.¹⁷ Stock cultures for Lr 231 were preserved in 10% skimmed milk at 4°C until further used for the experiment. Actively growing Lr 231 (2ml) were inoculated in MRS broth (100ml) and incubated at 37°C for 24 h. The cells were harvested by centrifugation at 5000 rpm for 15 min at 4°C and washed twice with PBS (pH 7, 0.1 M) and re-suspended in phosphate buffer (pH 7, 0.1 M) with optical density of 1.0 at 600 nm. The viability of the culture was determined by serial dilution method.

Study animals. Male Wistar rats (6–9 week old, 160–270 g) were maintained in an air conditioned room (22 ± 2°C, RH 55 ± 5%) approved by Institutional Animal Ethics Committee (CPCSEA, SU/DPS/IAEC/9013) and exposed to equal hours of light and dark cycle, fed with water and normal chow ad libitum.




Figure 3. Schematic diagram showing experimental plan used in present study.

Experimental design. Experimental design adopted for present study is shown in **Figure 3**. Animals were divided into three groups (n = 6). Positive and negative controls received PBS daily. Lr 231 group were fed intragastrically with fresh Lr 231 (10^{10} cfu/ kg body weight). On 21st and 28th day, MNNG (15 mg/ kg) was given intragastrically to positive control and Lr 231 groups, respectively²⁴ and daily food intake and body weights were measured. Fresh fecal samples were collected weekly to determine the fecal azoreductase and nitroreductase enzyme activities. On 30th day, rats were sacrificed using chloroform as anesthetic agent; liver, spleen and colon were removed and processed for biochemical and histological studies.

Fecal azoreductase and nitroreductase assay. Fecal samples collected from each group were prepared in 5% phosphate buffer (pH 6.8). Homogenized samples were centrifuged (5,000 rpm × 15 min, 4°C) and filtered using 0.45 µm millipore filter; and were used for azoreductase and nitroreductase assay.²⁵

Azoreductase assay. Fecal samples (3 ml) were homogenized in 0.1 ml of amaranth (7.75 mM), warmed (37°C) and incubated at 37°C for 1 h. An aliquot (0.3 ml) made up to 3 ml in 1 mM sodium azide solution, was centrifuged (12,000 rpm × 15 min, 4°C) using (Remi) and absorbance (A_{521}) of supernatant was measured using UV-Visible spectrophotometer (Shimadzu). Phosphate buffer (0.1M) was used as blank. Concentrations of the residual substrate were calculated using standard curve of amaranth, and specific enzyme activity was determined.

Nitroreductase assay. Fecal sample diluted (1:5) in 1.5 mM M-nitro benzoic acid (pH 6.8) were incubated anaerobically at 37°C for 1 h, using vacuum desiccator (Polylab) containing sodium thiosulphate as oxygen scavenger and anhydrous calcium sulfate was used as desiccant. Enzyme activity was arrested using 1.2 N HCl, centrifuged (5,000 rpm, 15 min, 4°C) and absorbance (A_{266}) of supernatant was measured. Phosphate buffer was used as blank.

Histopathology. Liver, spleen and colon were washed in 10% buffered formalin and fixed in Bouin's fixative. Tissues were then subjected to serial dilutions of alcohol (10–100%) and alcohol-xylene mix; and thereafter, were embedded in paraffin blocks and sectioned for histopathological study. Eosin yellow was used for staining and the sections were photographed. Histopathological sections were given scores according to the degree of inflammation by a blinded pathologist.²⁶

Antioxidative enzymes activity. Liver, spleen and colon were washed and homogenized (10%) using chilled normal saline and evaluated for glutathione transferase and glutathione reductase activity. All analysis was performed at 4°C.

Glutathione transferase activity (GST). GSH transferase activity was measured spectrophotometrically.²⁷ The reaction mixture (3 ml) containing 1 ml phosphate buffer (0.1 M, pH 7), 0.1 ml of 1-chloro-2, 4-dinitrobenzene (CDNB) (30 mM) and 1.7 ml distilled water were pre-incubated (37°C, 5 min). The reaction was initiated by adding 0.1 ml of tissue homogenate and 0.1 ml glutathione (5mM) as substrate. Absorbance was determined at 340 nm at 0 and 5 min. CDNB was omitted from the control tube. The reaction mixture without enzyme was used as blank. The activity of GST is expressed as µmoles of GSH-CDNB conjugate formed/min/mg protein using extinction coefficient of 9.6/mM/cm.

Glutathione reductase activity. Reaction mixture containing 200 mM phosphate buffer (pH 7) and 2 mM EDTA (pH 9), were homogenized with tissue and reaction was initiated by the adding 10 mM DTNB in phosphate buffer (pH 7). The sulphhydryl groups available in glutathione formed colored complex with DTNB that was measured instantaneously using colorimeter at 412 nm. The extinction coefficient of 1.36×10^{-7} /mM/cm was used for calculation and results were expressed as µmol of GSH/min/ mg of protein.^{28,29}

Protein estimation. Total protein in fecal sample and homogenized liver, spleen and colon was determined.³⁰

Statistical analysis. All the results obtained were statistically analyzed and were expressed as means ± SD (n as indicated). Comparisons were done with the statistical software package (SPSS 7.0). Differences in treatments were evaluated by one-way ANOVA followed by a Student's t-test; and the differences were considered significant.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors gratefully acknowledge Dr. H.V. Oza, Head and Professor of Department of Pathology, Dr. Grishma Jobanputra, P.D.O. Medical College, Rajkot and Dr. Arpita P. Rathod, Consultant pathologist and microbiologist at B.T. Savani Kidney Hospital, Rajkot, for their sincere support and invaluable assistance in facilitating the histopathological studies. Sincere regards to Dr. Ramadasan Kuttan, Amala Cancer Research Center, Kerala, India for providing MNNG, and Dr. Kanthi Kiran Kondepudi, Labmedicin, Klinisk Mikrobiologi, Division of Bacteriology, Lund University for the critical corrections of the MS.

References

1. Fearon ER, Vogelstein BA. Genetic model for colorectal tumorigenesis. *Cell* 1990; 61:759-67; PMID: 2188735; [http://dx.doi.org/10.1016/0092-8674\(90\)90186-1](http://dx.doi.org/10.1016/0092-8674(90)90186-1)
2. de Kok TM, van Maanen JM. Evaluation of fecal mutagenicity and colorectal cancer risk. *Mutat Res* 2000; 463:53-101; PMID:10838209; [http://dx.doi.org/10.1016/S1383-5742\(00\)00003-X](http://dx.doi.org/10.1016/S1383-5742(00)00003-X)
3. Ferguson LR, Philpott M, Karunasinghe N. Dietary cancer and prevention using antimutagens. *Toxicology* 2004; 198:147-59; PMID:15138038; <http://dx.doi.org/10.1016/j.tox.2004.01.035>
4. Rafter J, Bennett M, Caderni G, Clune Y, Hughes R, Karlsson PC, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. *Am J Clin Nutr* 2007; 85:488-96; PMID:17284748
5. Rauch M, Lynch SV. Probiotics manipulation of the gastrointestinal microbiota. *Gut Microbes* 2010; 1: 335-8; PMID:21327043; <http://dx.doi.org/10.4161/gmic.1.5.13169>
6. De Preter V, Hamer HM, Windey K, Verbeke K. The impact of pre- and/or probiotics on human colonic metabolism: Does it affect human health? *Mol Nutr Food Res* 2011; 55:46-57; PMID:21207512; <http://dx.doi.org/10.1002/mnfr.201000451>
7. Ljungh Å, Wadström T. Lactic acid bacteria as probiotics. *Curr Issues Intest Microbiol* 2006; 7:73-89; PMID:16875422
8. O'Flaherty S, Saulnier DM, Pot B, Versalovic J. How can probiotics and prebiotics impact mucosal immunity? *Gut Microbes* 2010; 1:293-300; PMID:21327037; <http://dx.doi.org/10.4161/gmic.1.5.12924>
9. Commane D, Hughes R, Shortt C, Rowland I. The potential mechanisms involved in the anti-carcinogenic action of probiotics. *Mutat Res* 2005; 591:276-89; PMID:16095630; <http://dx.doi.org/10.1016/j.mrfmmm.2005.02.027>

10. Liong MT. Roles of probiotics and prebiotics in colon cancer prevention: Postulated mechanisms and *in-vivo* evidence. *Int J Mol Sci* 2008; 9:854-63; PMID: 19325789; <http://dx.doi.org/10.3390/ijms9050854>
11. Vorobjeva LI, Abilev SK. Antimutagenic properties of bacteria. [review]. *Appl Biochem Microbiol* 2002; 38: 115-27; <http://dx.doi.org/10.1023/A:1014338712108>
12. Lidbeck A, Nord CE, Gustafson JA, Rafter J. Effect of *Lactobacillus acidophilus* supplements on mutagen excretion in feces and urine in humans Lactobacilli, anticarcinogenic activities and human intestinal microflora. *Eur J Cancer Prev* 1992; 1:341-53; PMID:1463986; <http://dx.doi.org/10.1097/00008469-199208000-00002>
13. IARC Monographs. 1974; 4:183-95.
14. Bingham SA, Pignatelli B, Pollock JR, Ellul A, Malaveille C, Gross G, et al. Does increased endogenous formation of N-nitroso compounds in the human colon explain the association between red meat and colon cancer? *Carcinogenesis* 1996; 17:515-23; PMID:8631138; <http://dx.doi.org/10.1093/carcin/17.3.515>
15. Ambalam P, Dave JM, Nair BM, Vyas BR. *In vitro* mutagen binding and antimutagenic activity of human *Lactobacillus rhamnosus* 231. *Anaerobe* 2011; 17: 217-22; PMID:21777684; <http://dx.doi.org/10.1016/j.anaerobe.2011.07.001>
16. Levi F, La Vecchia C, Lucchini F, Te VC, Franceschi S. Mortality from Hodgkin's disease and other lymphomas in Europe, 1960-1990. *Oncology* 1995; 52:93-6; PMID: 7854782; <http://dx.doi.org/10.1159/000227437>
17. Ambalam PS, Prajapati JB, Dave JM, Nair BM, Ljungh Å, Vyas BRM. Isolation and characterization of antimicrobial proteins produced by a potential probiotic strain of human *Lactobacillus rhamnosus* 231 and its effect on selected human pathogens and food spoilage organisms. *Microb Ecol Health Dis* 2009; 21:211-20; <http://dx.doi.org/10.3109/08910600903429052>
18. Gorbach SL, Goldin BR. The intestinal microflora and the colon cancer connection. *Rev Infect Dis* 1990; 12: S252-61; PMID:2154844; http://dx.doi.org/10.1093/clinids/12.Supplement_2.S252
19. Goldin BR, Gorbach SL. Alteration of the intestinal microflora by diet, oral antibiotics and *Lactobacillus*: decreased production of free amines from aromatic nitro compounds, azo dyes and glucuronides. *J Natl Cancer Inst* 1984; 73:689-95; PMID:6433097
20. Pool-Zobel BL, Bertram B, Knoll M, Lambertz R, Neudecker C, Schillinger U, et al. Antigenotoxic properties of lactic acid bacteria *in vivo* in the gastrointestinal tract of rats. *Nutr Cancer* 1993; 20: 271-81; PMID:8108276; <http://dx.doi.org/10.1080/01635589309514295>
21. Lee SM, Lee WK. Effect of lactic acid bacteria on intestinal microbial enzyme activity and composition in rats treated with azoxymethane. *J Microbiol* 2001; 39:154-61.
22. Sherratt JP, Hayes JD. Glutathione S-transferase. In: Ioannides C, ed. *Anderson D, Waters MD, Timothy CM, Series eds. Enzyme Systems that Metabolize Drugs and Other Xenobiotics*. New York: John Wiley & Sons, Ltd, 2002: 319-352.
23. Kumaresan KR, Springhorn SS, Lacks SA. Lethal and mutagenic actions of N-methyl-N'-nitro-N-nitrosoguanidine potentiated by oxidized glutathione, a seemingly harmless substance in the cellular environment. *J Bacteriol* 1995; 177:3641-6; PMID:7601826
24. Wollowski I, Ji ST, Bakalinsky AT, Neudecker C, Pool-Zobel BL. Bacteria used for the production of yogurt inactivate carcinogen and prevent DNA damage in the colon of rats. *J Nutr* 1999; 129:77-82; PMID:9915879
25. Carman RJ, Woodburn MA. Azoreductase and nitroreductase in human feces: Comparison of methods to measure specific activities in the absence of oxygen. *Microb Ecol Health Dis* 1999; 11:208-10; <http://dx.doi.org/10.1080/08910609908540829>
26. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. *J Hepatol* 1995; 22:696-9; PMID:7560864; [http://dx.doi.org/10.1016/0168-8278\(95\)80226-6](http://dx.doi.org/10.1016/0168-8278(95)80226-6)
27. Habig WH, Pabst MJ, Jakoby WB. Glutathione-S-transferase: the first enzymatic step in mercapturic acid formation. *J Biol Chem* 1974; 249:7130-9; PMID: 4436300
28. Ellman GL. Tissue sulfhydryl groups. *Arch Biochem Biophys* 1959; 82:70-7; PMID:13650640; [http://dx.doi.org/10.1016/0003-9861\(59\)90090-6](http://dx.doi.org/10.1016/0003-9861(59)90090-6)
29. Smith IK, Vierheller TL, Thorne CA. Assay of glutathione reductase in crude tissue homogenates using 5, 5'-dithiobis (2-nitrobenzoic acid). *Anal Biochem* 1988; 175:408-13; PMID:3239770; [http://dx.doi.org/10.1016/0003-2697\(88\)90564-7](http://dx.doi.org/10.1016/0003-2697(88)90564-7)
30. Lowry OH, Rosebrough NF, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. *J Biol Chem* 1951; 193:265-75; PMID:14907713

Landes Bioscience.
Do not distribute.